{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Incyte Corporation"},"Symbol":{"label":"Symbol","value":"INCY"},"Address":{"label":"Address","value":"1801 AUGUSTINE CUT-OFF, WILMINGTON, Delaware, 19803, United States"},"Phone":{"label":"Phone","value":"+1 302 498-6700"},"Industry":{"label":"Industry","value":"Biotechnology: Commercial Physical & Biological Resarch"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs."},"CompanyUrl":{"label":"Company Url","value":"https://www.incyte.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Herve Hoppenot","title":"Chairman, President & Chief Executive Officer"},{"name":"Pablo J. Cagnoni","title":"President-Research & Development"},{"name":"Steven H. Stein","title":"Chief Medical Officer & Executive Vice President"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}